1型神经纤维瘤病相关肺动脉高压的表型与结局
基于法国肺动脉高压注册队列,报告49例1型神经纤维瘤病相关肺动脉高压(PH-NF1)患者的临床、功能、影像、病理及血流动力学特征。患者以女性为主,诊断时中位年龄62岁,表现为低DlCO、严重低氧血症和严重毛细血管前性肺动脉高压,接受PAH药物治疗后功能分级与血流动力学改善,但无移植生存率仍低。
要点
- PH-NF1以女性为主,诊断时多为NYHA功能III或IV级,DlCO低且低氧血症严重。
- 右心导管示严重毛细血管前性肺动脉高压,PAH药物可改善功能分级与血流动力学。
- 无移植生存率1年87%、3年54%、5年42%,符合条件者可考虑双肺移植。
核心结论
- PH-NF1以女性 predominance、低DlCO及严重功能与血流动力学损害为特征,尽管PAH治疗可能有获益,预后仍差,双肺移植是合适患者的选择。
研究设计与样本
- 来自法国肺动脉高压注册队列的PH-NF1病例系列,共49例,收集临床、功能、影像、病理及血流动力学资料并分析PAH药物反应与无移植生存。
- 女性/男性比为3.9,诊断时中位(最小-最大)年龄为62(18-82)岁。
主要发现
- 诊断时92%为NYHA功能III或IV级,6分钟步行距离为211(0-460)m。
- 肺功能示低DlCO(30%[12-79%])和严重低氧血症(PaO2 56[38-99] mm Hg)。
- 右心导管示严重毛细血管前性肺动脉高压,平均肺动脉压45(10)mm Hg,肺血管阻力10.7(4.2)Wood单位。
- 高分辨率CT示囊肿76%、磨玻璃影73%、肺气肿49%、网格影39%。
关键数值与推荐
- PH-NF1诊断时92%为NYHA功能III或IV级。
- 6分钟步行距离211(0-460)m。
- DlCO 30%(12-79%),PaO2 56(38-99)mm Hg。
- 平均肺动脉压45(10)mm Hg,肺血管阻力10.7(4.2)Wood单位。
- 1、3、5年无移植生存率分别为87%、54%、42%。
临床怎么用
- 对NF1患者出现呼吸困难或低氧血症时应警惕PH-NF1,完善DlCO、右心导管和HRCT评估。
- PAH获批药物可考虑用于PH-NF1以改善功能分级和血流动力学,但需认识预后仍差。
- 符合条件者应评估双肺移植指征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Pulmonary hypertension (PH) associated with neurofibromatosis type 1 (NF1) is a rare and largely unknown complication of NF1.Objectives: To describe characteristics and outcomes of PH-NF1.Methods: We reported the clinical, functional, radiologic, histologic, and hemodynamic characteristics, response to pulmonary arterial hypertension (PAH)-approved drugs, and transplant-free survival of patients with PH-NF1 from the French PH registry.Measurements and Main Results: We identified 49 PH-NF1 cases, characterized by a female/male ratio of 3.9 and a median (minimum-maximum) age at diagnosis of 62 (18-82) years. At diagnosis, 92% were in New York Heart Association functional class III or IV. The 6-minute-walk distance was 211 (0-460) m. Pulmonary function tests showed low DlCO (30% [12-79%]) and severe hypoxemia (PaO2 56 [38-99] mm Hg). Right heart catheterization showed severe precapillary PH with a mean pulmonary artery pressure of 45 (10) mm Hg and a pulmonary vascular resistance of 10.7 (4.2) Wood units. High-resolution computed tomography images revealed cysts (76%), ground-glass opacities (73%), emphysema (49%), and reticulations (39%). Forty patients received PAH-approved drugs with a significant improvement in functional class and hemodynamic parameters. Transplant-free survival at 1, 3, and 5 years was 87%, 54%, and 42%, respectively, and four patients were transplanted. Pathologic assessment showed nonspecific interstitial pneumonia and major pulmonary vascular remodeling.Conclusions: PH-NF1 is characterized by a female predominance, a low DlCO, and severe functional and hemodynamic impairment. Despite a potential benefit of PAH treatment, prognosis remains poor, and double-lung transplantation is an option for eligible patients.
引用
- Jutant EM, Jaïs X, Girerd B, et al. Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. Am J Respir Crit Care Med. 2020. PMID: 32437637. doi:10.1164/rccm.202001-0105OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。